Drug Update

The Food and Drug Administration (FDA) is continuously approving new drugs, and we want to ensure our Clients are aware of these new approvals and drugs as they enter the market. The table below includes the drugs that are most likely to impact your plan. The full list of recent approvals can be found below the chart.

 

Posted: Feb 20 2017

FDA Drug Approvals

Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months. Therefore, pricing information for these medications is typically unavailable at the time of approval.

New Brand Approvals
Drug Name Uses/Treatment Pricing Information Other Information
Trulance (plecanatide) Treatment of chronic idiopathic constipation in adult patients Pricing information not yet available
  • Drug Information: Trulance is available as a 3mg oral tablet taken once daily with or without food.
  • Formulary Management: Considered non-preferred upon market entry.
  • Control Trak: Subject to Max Dollar and Max Dose edits.
Xyzal Allergy 24 HR (levocetirizine) Treatment of seasonal allergic ehinitis and perennial allergic rhinitis in pediatric and adult patients Pricing information not yet available
  • Drug Information: Prescription Xyzal is currently available as a tablet, oral liquid, and quick-dissolving tablet. Xyzal Allergy 24 HR is the first over-the-counter (OTC) formulation of levocetirizine and will be available as on oral tablet and oral solution.
  • Control Trak: Subject to Max Dollar and Max Dose edits.
  • Clinical Concierge: Xyzal Allergy 24 HR will be evaluated by MedTrakRx’s Clinical team for inclusion within the RX to OTC Program.
Vantrela ER (hydrocodone bitartrate) Treatment of severe pain in adult patients who require daily, around-the-clock, long-term opioid treatment Pricing information not yet available
  • Drug Information: Vantrela ER is the third extended-release hydrocodone product to come to the market, following Zohydro ER and Hysingla ER.
  • Formulary Management: Considered non-preferred upon market entry.
  • Control Trak: Vantrela ER is a C-II opioid analgesic and will be added to the MedTrakRx Chronic Use Program.



Download Report as PDF
Search Drug Updates